SEARCH

SEARCH BY CITATION

References

  • 1
    Lau JYN, Standring DN. Development of novel therapies for hepatitis C. In: LiangTJ, HoofnagleJH, eds. Hepatitis C: Biomedical Research Reports. 1st ed. London, Academic Press, 2000; 453467.
  • 2
    Dymock BW. Emerging therapies for hepatitis C virus infection. Emerg Drugs 2001; 6:1342.
  • 3
    Mercer DF, Schiller DE, Elliot JF, Douglas DN, Hao C, Rinfret A, Addison WR, et al. Hepatitis C virus replication in mice with chimeric human livers. Nat Med 2001; 7:927933.MEDLINE
  • 4
    Lohmann V, Korner F, Koch J, Herian U, Theilmann L, Bartenschlager R. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 1999; 285:110113.MEDLINE
  • 5
    Pockros PJ. Developments in treatment of chronic hepatitis C. Expert Opin Invest Drugs 2002; 11:114.
  • 6
    Lau JY, Tam RC, Liang TJ, Hong Z. Mechanism of action of ribavirin in the combination treatment of chronic HCV infection. Hepatology 2002; 35: 10021009MEDLINE
  • 7
    Lin C-C, Luu K, Lourenco D, Corritori S, Hong Z, Lau JY. Viramidine, a prodrug of ribavirin, demonstrated superior liver-targeting properties and much improved toxicity profile in cynomolgus monkey studies [Abstract]. Hepatology 2001; 34(Suppl.):453A.
  • 8
    Lau JY, Lin C-C. Assessment of liver delivery of ribavirin and viramidine, a liver-targeting ribavirin prodrug, using whole body autoradiography [Abstract]. Hepatology 2001; 34(Suppl.):427A.
  • 9
    McHutchison JG, Cheung R, Shiffman ML, Wright T, Gordon SC, Knox SJ, Ette E, et al. A 4-week trial of VX 497 (an IMPDH inhibitor) combined with interferon in previously untreated patients with chronic hepatitis C [Abstract]. Hepatology 2001; 34(Suppl.):329A.
  • 10
    Afdhal N, Flamm S, Imperial JC, Malet PF, Tong M, Herrine SK, Brown Jr R, et al. Analyses of 40 KDA peginterferon alfa-2a in combination with ribavirin, mycophenolate mofetil, amantadine or amantadine plus ribavirin in patients that relapsed or did not respond to Rebetron therapy: a report of two randomized, multicenter, efficacy and safety studies [Abstract]. Hepatology 2001; 34(Suppl.):243A.
  • 11
    Lurie Y, Pakula R, Malnick S, Beer-Gabel M, Gehlsen KR. Efficacy and safety of the combination of histamine dihydrochloride and interferon alpha-2b in a phase II trial in naive patients with chronic hepatitis C [Abstract]. Hepatology 2001; 34(Suppl.):350A.
  • 12
    Craxi A, Lo Iacono O. Amantadine for chronic hepatitis C: a magic bullet or yet another dead duck. J Hepatol 2001; 35:527530.MEDLINE
  • 13
    Bartenschlager R, Lohmann V. Replication of hepatitis C virus. J Gen Virol 2000; 81:16311648.MEDLINE
  • 14
    Steinkuhler C, Koch U, Narjes F, Matassa VG. Hepatitis C virus serine protease inhibitors: current progress and future challenges. Curr Med Chem 2001; 8:919932.MEDLINE
  • 15
    Myles DC. Recent advances in the discovery of small molecule therapies for HCV. Curr Opin Drug Discov Devel 2001; 4:411416.MEDLINE
  • 16
    Zhang X. Inhibitors of hepatitis C: a review of the recent patent literature. IDrugs 2002; 5:154158.
  • 17
    Witherell GW. ISIS-14803 (ISIS Pharmaceuticals). Curr Opin Invest Drugs 2001; 2:15231529.
  • 18
    McHutchison JG, Pockros P, Nyberg LM, Kwoh TJ, Dorr FA. A dose escalation study of ISIS 14803, an antisense inhibitor of HCV, in chronichepatitis C patients [Abstract]. Hepatology 2001; 34(Suppl.):350A.
  • 19
    Lee PA, Blatt LM, Blanchard KS, Bouhana KS, Pavco PA, Bellon L, Sandberg JA. Pharmacokinetics and tissue distribution of a ribozyme directed against hepatitis C virus RNA following subcutaneous or intravenous administration in mice. Hepatology 2000; 32:640646.MEDLINE
  • 20
    Reeves HL, Friedman SL. Activation of hepatic stellate cells: a key issue in liver fibrosis. Front Biosci 2002; 7:808826.
  • 21
    Frese M, Schwarzle V, Barth K, Krieger N, Lohmann V, Mihm S, Haller O, et al. Interferon-gamma inhibits replicaton of subgenomic and genomic hepatitis C virus RNAs. Hepatology 2002; 35:694703.MEDLINE
  • 22
    Ziesche R, Hofbauer E, Wittmann K, Petkov V, Lutz-Henning B. A preliminary study of long-term treatment with interferon gamma-1b and low-dose prednisolone in patients with idiopathic pulmonary fibrosis. N Engl J Med 1999; 341: 12641269.MEDLINE
  • 23
    Nelson D, Soldevila-Pico C, Abdelmalek M, Xu Y, Sampson D, Kao KJ, Davis G. Long-term use of recombinant interleukin 10 (IL-10) in patients with advanced chronic hepatitis C: insight into immunopathogenesis [Abstract]. Hepatology 2001; 34(Suppl.):430A.
  • 24
    Di Bisceglie AM, McHutchison J, Rice CM. New therapeutic strategies for hepatitis C. Hepatology 2002; 35:224231.MEDLINE